LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 400

Suchoptionen

  1. Artikel ; Online: Thirst and drugs: A study in the World Health Organization's pharmacovigilance database.

    Montastruc, Jean-Louis

    British journal of clinical pharmacology

    2024  Band 90, Heft 6, Seite(n) 1525–1528

    Abstract: Thirst is a complex physiological compensatory mechanism but could also be associated with drugs. This association was poorly investigated previously. Using the WHO global pharmacovigilance database, Vigibase®, disproportionality analyses potential ... ...

    Abstract Thirst is a complex physiological compensatory mechanism but could also be associated with drugs. This association was poorly investigated previously. Using the WHO global pharmacovigilance database, Vigibase®, disproportionality analyses potential associations between exposure to drugs and thirst reports were performed. All reports of thirst in adults between 01/01/2000 and 31/12/2023 were included. Results are expressed as reporting odds ratio (ROR). Analysis of the 3186 reports of thirst (978 'serious') allowed, first, to confirm the association between thirst and exposure to vasopressin antagonists (tolvaptan), lithium, gliflozins (dapagliflozin, empagliflozin), pregabalin and antimuscarinic drugs (glycopyronium, oxybutynin, tiotropium). Second, new safety signals were described with monoamine reuptake inhibitors (antidepressants: duloxetine, venlafaxine; anti-obesity agent: sibutramine), antipsychotic (olanzapine), glucocorticoid (prednisolone), diuretic (furosemide) drugs as well with ribavirin or sodium oxybate. This study is the first to offer a list of drugs associated with thirst in humans.
    Mesh-Begriff(e) Humans ; Pharmacovigilance ; Databases, Factual/statistics & numerical data ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Thirst/drug effects ; Male ; World Health Organization ; Female ; Adult ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Middle Aged ; Aged ; Young Adult
    Sprache Englisch
    Erscheinungsdatum 2024-04-16
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.16080
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Drug-induced diseases: A worrying, neglected, preventable, serious and costly epidemic.

    Montastruc, Jean-Louis

    Therapie

    2023  Band 79, Heft 2, Seite(n) 151–154

    Mesh-Begriff(e) Humans ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/prevention & control
    Sprache Englisch
    Erscheinungsdatum 2023-10-31
    Erscheinungsland France
    Dokumenttyp Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2023.10.007
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Safety of pitolisant: a study in the WHO international pharmacovigilance database.

    Montastruc, Jean-Louis

    European journal of clinical pharmacology

    2023  Band 79, Heft 4, Seite(n) 569–570

    Mesh-Begriff(e) Humans ; Pharmacovigilance ; Piperidines ; Databases, Factual ; World Health Organization ; Adverse Drug Reaction Reporting Systems ; Drug-Related Side Effects and Adverse Reactions
    Chemische Substanzen pitolisant (4BC83L4PIY) ; Piperidines
    Sprache Englisch
    Erscheinungsdatum 2023-03-09
    Erscheinungsland Germany
    Dokumenttyp Journal Article
    ZDB-ID 121960-1
    ISSN 1432-1041 ; 0031-6970
    ISSN (online) 1432-1041
    ISSN 0031-6970
    DOI 10.1007/s00228-023-03460-0
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.

    Montastruc, Jean-Louis

    British journal of clinical pharmacology

    2023  Band 89, Heft 8, Seite(n) 2636–2638

    Abstract: Rhabdomyolysis is a serious adverse drug reaction of statins. There are few studies comparing the risk of rhabdomyolysis between the different statins. Using the WHO pharmacovigilance database, VigiBase®, we compared the risk of rhabdomyolysis reporting ... ...

    Abstract Rhabdomyolysis is a serious adverse drug reaction of statins. There are few studies comparing the risk of rhabdomyolysis between the different statins. Using the WHO pharmacovigilance database, VigiBase®, we compared the risk of rhabdomyolysis reporting of seven statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, with cerivastatin excluded). All reports of rhabdomyolysis in VigiBase® in adults with statins until 31 December 2022 were included. Results are expressed as reporting odds ratio (ROR, 95% CI). Among 10 657 reports with rhabdomyolysis with statins, simvastatin was the highest risk statin in comparison with others: ROR = 2.20 (2.11-2.29). The risk was higher in men, older than 74 years and in cases of drug interactions.
    Mesh-Begriff(e) Male ; Adult ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Pharmacovigilance ; Simvastatin/adverse effects ; Atorvastatin ; Rhabdomyolysis/chemically induced ; Rhabdomyolysis/epidemiology
    Chemische Substanzen Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Simvastatin (AGG2FN16EV) ; Atorvastatin (A0JWA85V8F)
    Sprache Englisch
    Erscheinungsdatum 2023-05-08
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15757
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database.

    Montastruc, Jean-Louis

    British journal of clinical pharmacology

    2023  Band 89, Heft 12, Seite(n) 3765–3768

    Abstract: Bruxism is a movement disorder of uncertain aetiology. Beside local peripheral and central psychological factors, drugs were suspected. Using the World Health Organization (WHO) global pharmacovigilance database, Vigibase®, we investigated through ... ...

    Abstract Bruxism is a movement disorder of uncertain aetiology. Beside local peripheral and central psychological factors, drugs were suspected. Using the World Health Organization (WHO) global pharmacovigilance database, Vigibase®, we investigated through disproportionality analyses potential associations between exposure to drugs and bruxism reports. All reports of bruxism in adults between 01/01/2000 and 31/12/2022 were included. Results are expressed as reporting odds ratio (ROR). Among the 564 reports of bruxism, an association was found with eight antidepressants (first sertraline followed by escitalopram, venlafaxine, vortioxetine, citalopram, paroxetine, fluoxetine, duloxetine) and four antipsychotics (first ziprasidone followed by aripiprazole, olanzapine, risperidone). A signal was also described for oxybate sodium and metoclopramide. For antidepressants, a negative association was found between ROR values and NET (norepinephrine transporter) but not SERT (serotonin transporter) pKi values, suggesting this ADR is more closely linked to norepinephrine than serotonin reuptake inhibition.
    Mesh-Begriff(e) Adult ; Humans ; Selective Serotonin Reuptake Inhibitors/adverse effects ; Pharmacovigilance ; Bruxism ; Antidepressive Agents/adverse effects ; World Health Organization
    Chemische Substanzen Selective Serotonin Reuptake Inhibitors ; Antidepressive Agents
    Sprache Englisch
    Erscheinungsdatum 2023-08-30
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15884
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Adverse drug reactions and ivermectin in COVID-19.

    Montastruc, Jean-Louis

    Therapie

    2022  

    Sprache Englisch
    Erscheinungsdatum 2022-04-27
    Erscheinungsland France
    Dokumenttyp Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2022.04.003
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Pharmacovigilance and drug safety: Fair prescribing and clinical research.

    Montastruc, Jean-Louis

    Therapie

    2022  Band 77, Heft 3, Seite(n) 261–263

    Mesh-Begriff(e) Adverse Drug Reaction Reporting Systems ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Humans ; Pharmacovigilance
    Sprache Englisch
    Erscheinungsdatum 2022-05-05
    Erscheinungsland France
    Dokumenttyp Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2022.03.001
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Fatal adverse drug reactions in children: A descriptive study in the World Health Organization pharmacovigilance database, 2010-2019.

    Montastruc, Jean-Louis

    British journal of clinical pharmacology

    2022  Band 89, Heft 1, Seite(n) 201–208

    Abstract: Aims: Adverse drug reactions (ADRs) represent a significant public health burden. There are few data on fatal ADRs in children. This population is particularly at risk due to metabolic and physiological immaturity, frequent off-label drug use and ... ...

    Abstract Aims: Adverse drug reactions (ADRs) represent a significant public health burden. There are few data on fatal ADRs in children. This population is particularly at risk due to metabolic and physiological immaturity, frequent off-label drug use and limited paediatric clinical pharmacology studies. The study investigated the main characteristics of drug-related deaths registered in World Health Organization pharmacovigilance database, during the past decade.
    Methods: Fatal outcomes registered between 2010 and 2019 in children (<18 y) and reported by physicians were investigated. Age, sex and suspected drugs were described and disproportionality analyses investigated differences according to sex, age and continents with calculation of reporting odds ratio and its 95% confidence interval.
    Results: Among the 1 198 560 reports registered in children, 1585 (0.13%) were fatal. They occurred mainly in boys, aged 28 days-23 months. Reports mostly came from the Americas and Europe and involved, besides anti-infectious drugs (mainly vaccines), central nervous system (vigabatrin, paracetamol, methylphenidate…) and antineoplastic/immunomodulating (mainly thalidomide) and cardiovascular (mainly bosentan) drugs without major differences between boys and girls. Large differences were found according to continents and age. The risk of reporting was higher in boys, in children aged <23 months, in the Americas and Africa.
    Conclusion: Fatal ADRs represented a small part (around 1/1000) of total registered ADRs, occurred more frequently in boys and during the first 2 years of life. Beside anti-infectious drugs (vaccines), neuropsychiatric drugs were the most frequently involved, with large differences according to continents and classes of age.
    Mesh-Begriff(e) Male ; Female ; Humans ; Child ; Pharmacovigilance ; Off-Label Use ; Adverse Drug Reaction Reporting Systems ; Drug-Related Side Effects and Adverse Reactions ; Databases, Factual ; World Health Organization
    Sprache Englisch
    Erscheinungsdatum 2022-08-17
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 188974-6
    ISSN 1365-2125 ; 0306-5251 ; 0264-3774
    ISSN (online) 1365-2125
    ISSN 0306-5251 ; 0264-3774
    DOI 10.1111/bcp.15470
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: 1921-2021, from insulin to new hypoglycaemic drugs: 100 years of pharmacological research in diabetes mellitus.

    Montastruc, Jean-Louis

    Therapie

    2021  Band 76, Heft 6, Seite(n) 517–521

    Mesh-Begriff(e) Diabetes Mellitus/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hypoglycemic Agents ; Insulin
    Chemische Substanzen Hypoglycemic Agents ; Insulin
    Sprache Englisch
    Erscheinungsdatum 2021-09-22
    Erscheinungsland France
    Dokumenttyp Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2021.09.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Un prix éditorial pour un article publié dans THERAPIES en 2020 : « La pharmacogénétique au service du soin en France : une discipline qui évolue ! ».

    Montastruc, Jean-Louis

    Therapie

    2021  Band 77, Heft 1, Seite(n) 1–2

    Titelübersetzung An editorial award for an article published in THERAPIES in 2020: "Pharmacogenetics for health care in France: An evolving discipline!"
    Sprache Französisch
    Erscheinungsdatum 2021-11-25
    Erscheinungsland France
    Dokumenttyp Editorial
    ZDB-ID 603474-3
    ISSN 1958-5578 ; 0040-5957
    ISSN (online) 1958-5578
    ISSN 0040-5957
    DOI 10.1016/j.therap.2021.11.008
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang